Why the study?
Does doxorubicin-cyclophosphamide improve objective response rates compared to cyclophosphamide-methotrexate-5-fluorouracil-vincristine-prednisone in patients with metastatic breast carcinoma?
Population
102 patients with metastatic breast carcinoma
Comparison
Doxorubicin-cyclophosphamide (DC) vs Cyclophosphamide-methotrexate-5-fluorouracil-vinc…
Design
RCT, Randomized to either doxorubicin-cyclophosphamide or…
Authors
Loading...
DC does not improve objective response rates over CMFVP; supports CMFVP preference for higher complete responses and longer remission in metastatic breast cancer.
Does doxorubicin-cyclophosphamide improve objective response rates compared to cyclophosphamide-methotrexate-5-fluorouracil-vincristine-prednisone in patients with metastatic breast carcinoma?
In patients with metastatic breast carcinoma, the CMFVP regimen yielded higher complete response rates and longer remission duration with slightly less toxicity compared to the DC regimen.
Parvinen et al. (1985) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: